Table 2.
ECG characteristics at baseline and during flecainide.
| OM perfusion | LAD perfusion | |||
|---|---|---|---|---|
| Baseline | Flecainide (60 μM) | Baseline | Flecainide (6 μM) | |
| Total QRS, ms | 87 | 113 | 77 | 76 |
| INFEROLATERAL LEADS, n = 19 | ||||
| J-wave # leads, N/n | 1/19 | 10/19 | 4/19 | 0/19 |
| Jo, ms | 62 | 42 | 45 | - |
| A_dECG, mV | 0.22 (0.14–0.36) | −0.25 (−0.35—0.20) | ||
| OTHER LEADS, n = 42 | ||||
| J-wave # leads, N/n | 3/42 | 1/42 | 1/42 | 2/42 |
| Jo, ms | 55 | 55 | 48 | 34 |
| A_dECG, mV | −0.11 (−0.17—0.05) | 0.17 (−0.16—0.23) | ||
| QT interval, ms | 294 | 300 | 273 | 269 |
QRS, QRS duration; J-wave # leads, number of leads with J-wave (N) out of number of selected leads (n); Jo, first onset of J-wave; A_dECG, maximum or minimum amplitude of difference ECG [median (25th–75th percentile)].